Historically, the use of diuretics has been limited because of there side-effects. Currently, their use is increasing in a variety of clinical situations. They are used as single agent or in combination with other drugs. This study is a non randomized prospective clinical trial. 66 patients with nephropathy were enrolled in the study. Over the course of one year, each patient was treated for an average of 25 days with the loop diuretics Torasemide, Furosemide and Bumetanide and the thiazide diuretics Hydrochlorothiazide and Xipamide. In serum and urine sodium, potassium, calcium and magnesium were measured as well as serum creatinine and urea. Single agent therapy with Torasemide and Furosemide significantly reduced serum creatinine and urea. However Bumetanide did not lead to a significant reductions in these serum levels. Monotherapy with Bumetanide resulted in a significant reduction of albuminuria. There was seen a smaller tendency for hypokalemia with Torasemide and Bumetanide, but not with Furosemide or Xipamide. We also found that the loop diuretics, especially Furosemide cause hypocalcemia, whereas thiazide like Hydrochlorothiazide cause an anticalciuria. There was no statistically or clinically significant result found for therapy with the combination of Torasemide and Hydrochlorothiazide as well as single therapy with Xipamide.